# Supplementary material for New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with $M72/AS01_E$ and BCG-revaccination

Rebecca A. Clark et. al

#### **Table of Contents**

S	JPPLEN	IENTARY METHODS	3
1.	Mode	el structure and equations	3
	1.1	Natural history model structure	3
	1.2	Natural history model equations	4
2.	Natu	ral history	5
	2.1	Natural history parameter values and data sources	5
	2.2	Operationalising age varying parameters	7
	2.3	Treatment initiation and outcomes	8
3.	Mode	el simulation and calibration	9
	3.1	Model simulation	9
	3.2	Model calibration	9
	3.3	Incorporating the COVID-19 pandemic	10
	3.4	Modifications to calibration targets	12
	3.4.1	Tuberculosis prevalence targets	12
	3.4.2	Tuberculosis infection prevalence	14
	3.4.3	Tuberculosis case notifications	14
	3.4.4	Proportion of previously treated incident cases	16
4.	Polic	y scenarios	22
	4.1	No-new-vaccine baseline	22
	4.2	Vaccine delivery scenarios	22
	4.2.1	Classifying tuberculosis vaccines	22
	4.2.2	$M72/AS01_E$ and BCG-revaccination scenarios	23
	4.2.3	Vaccine delivery assumptions	23
	4.3	Vaccine model structure	24
	4.3.1	No Current Infection vaccines	25
	4.3.2	Current Infection vaccines	26
	4.3.3	Any Infection vaccines	27
5.	Econ	omic analysis methods	29
	5.1	Calculation of disability-adjusted life years	29
	5.2	Tuberculosis-related cost model	29

	5.3	Vaccine introduction	29
	5.4	Cost-effectiveness analysis and willingness-to-pay thresholds	29
6.	Heal	30	
SU	PPLEN	IENTARY RESULTS	31
7.	No-N	ew-Vaccine baseline	31
	7.1	No-New-Vaccine baseline calibration	31
	7.2	Posteriors distributions for model parameters	37
8.	Heal	th impact results	38
	8.1	M72/AS01 <sub>E</sub> scenarios	38
	8.2	BCG-revaccination scenarios	40
	8.3	India NTEP scenario	41
9.	Econ	omic results	42
	9.1	M72/AS01 <sub>E</sub> scenarios	42
	9.2	BCG-revaccination scenarios	46
Re	ference	S	50

#### SUPPLEMENTARY METHODS

#### 1. Model structure and equations

We created an age-stratified compartmental differential equation model of tuberculosis in India, including dimensions for age, tuberculosis natural history, vaccination, and access-to-care. The age and access-to-care structures are identical to those included in Clark et al.<sup>1</sup> Minor modifications from the Clark et al. natural history structure are described below. The vaccination structure is in section 4.3.

#### **1.1** Natural history model structure

A natural history structure with eight compartments in Figure S1.1 was created by adapting features of previous models and has been described previously.<sup>1</sup> The latency structure in this model demonstrates a progressive loss of ability to reactivate, with the reactivation rate in the Latent-Fast compartment greater than in Latent-Slow and greater still than in Latent-Zero, where we assume the rate of reactivation is 0. We do not explicitly have a self-clearance compartment. We assume that those in Latent-Fast can only fast progress to subclinical disease or continue to remain latent and transition to Latent-Slow. There is no direct transition between Latent-Fast and Latent-Zero.



#### Figure S1.1 Tuberculosis natural history model structure

Abbreviations:  $U_N = Uninfected$ -Naive;  $L_F = Latent$ -Fast;  $L_S = Latent$ -Slow;  $L_0 = Latent$ -Zero,  $D_S = Subclinical$ Disease;  $D_C = Clinical$  Disease; T = On-Treatment; R = Recovered. Subscript j represents parameters that vary by age, and subscript k represents parameters that vary over time.

#### 1.2 Natural history model equations

$$\begin{split} Age \ j &= 0 & Age \ j \neq 0 \\ \frac{dU_{N_j}}{dt} &= B_k - (\lambda_j + \mu_{j,k})U_{N_j} & \frac{dU_{N_j}}{dt} = -(\lambda_j + \mu_{j,k})U_{N_j} \\ \frac{dL_{F_j}}{dt} &= \lambda_j U_{N_i} + (1 - p_R)\lambda_j L_{0_i} + [(1 - p_R)\lambda_j]L_{S_i} - (\omega_{FS} + \theta_j + \mu_{j,k})L_{F_i} \\ \frac{dL_{S_j}}{dt} &= \omega_{FS} L_{F_i} - (\omega_{S0} + \sigma_j + (1 - p_R)\lambda_j + \mu_{j,k})L_{S_i} \\ \frac{dL_{0_j}}{dt} &= \omega_{S0} L_{S_i} - [(1 - p_R)\lambda_j + \mu_{j,k}]L_{0_i} \\ \frac{dD_{S_j}}{dt} &= \theta_j L_{F_j} + \sigma_j L_{S_j} + [\rho_j + (1 - p_R)\frac{\theta_j}{\theta_i + \omega}\lambda_j]R_j - (\chi + \zeta + \mu_{j,k})D_{S_j} \\ \frac{dD_{C_j}}{dt} &= \zeta D_{S_i} + \frac{f_{j,k}}{\tau}T_j - (\chi + \eta_{j,k} + \mu_{DC_i} + \mu_{j,k})D_{C_i} \\ \frac{dT_j}{dt} &= \eta_{j,k}D_{C_j} - \left(\frac{s_{j,k} + f_{j,k}}{\tau} + \mu_{T_{j,k}} + \mu_{j,k}\right)T_j \\ \frac{dR_j}{dt} &= \frac{s_{j,k}}{\tau}T_j + (D_{S_j} + D_{C_j})\chi - [\rho_j + (1 - p_R)\frac{\theta_j}{\theta_i + \omega}\lambda_j + \mu_{R_j} + \mu_{j,k}]R_j \end{split}$$

#### 2. Natural history

#### 2.1 Natural history parameter values and data sources

Parameters used in the natural history model structure are provided in Table S2.1 below, along with their definitions, sources, and information on whether the parameter is fixed or varied (as well as whether they are varied by age or time) during calibration. Further details about how the age varying parameters are implemented are provided in section 2.2, and further details on parameters related to treatment are provided in section 2.3. The parameter ranges provided for the tuberculosis natural history parameters are priors fitted during calibration in a Bayesian analysis. We assume that all values within the prior range are equally likely. The prior ranges were pre-specified based on literature review and were reviewed as new data became available.

#### Table S2.1 India national model parameter values and sources

Description	Units	Symbol	Prior	Fixed or Varying During Calibration	Age Varying	Time Varying	Source		
Births and deaths (excluding on-treatment mortality)									
Birth rate	Per year	$B_k$	United Nations World Population Prospects population estimates and projections	Fixed	No	Yes	2		
Background mortality rate	Per year	r $\mu_{j,k}$ Calculated in the model from United Nations population estimates and projections Fixed Fixed Fixed Yes, age specific mortality ra- from demographic dataset		Yes, age specific mortality rates from demographic dataset	Yes	2			
Mortality rate for clinical tuberculosis disease	Per person per year	$\mu_{DC_j}$	(0-0.178)	Varying	Yes, value for children is greater than value for adults	No	3		
Mortality rate post- tuberculosis disease	Per person per year	$\mu_{R_j}$	$0.22\mu_{j,k}$	Fixed relationship	Yes because $\mu_{j,k}$ varies	Yes because $\mu_{j,k}$ varies	4		
Natural History									
Force of infection	Per year	$\lambda_j$	Fitted	Fixed Equation	Yes, age specific contact rates <sup>5</sup>	No	Calculated		
Probability of transmission per infectious contact	-	$p_T$	(0-0.0068)	Varying	No	No	Assumed		

Fraction of total tuberculosis that is extrapulmonary	-	ep	0.222	Fixed	No	No	6,7
Infectiousness of subclinical relative to clinical tuberculosis	-	r	0.83	Fixed	No	No	8
Rate of fast progression to disease, by age	Per person per year	$ heta_j$	(0.0696–0.111)	Varying	Yes; Retain if value for children is <b>less</b> than value for adults.	No	9
Rate from $L_F$ to $L_S$	Per person per year	$\omega_{FS}$	0.5	Fixed	No	No	Defined
Rate of reactivation from $L_s$ , by age	Per person per year	σ	(0.000135–0.00113)	Varying	Yes; Retain if value for children is <b>less</b> than value for adults.	No	9
Rate from Ls to L0	Per person per year	$\omega_{S0}$	(0.0254–0.0467)	Fixed	No	No	9
Rate of progression from Ds to Dc	Per person per year	ζ	(0–12)	Varying	No	No	Assumed
Rate of natural cure from $D_C$ and $D_S$	Per person per year	$\chi$	(0.10–0.25)	Varying	No	No	10,11
Rate of relapse from R, by agePer person per year $\rho_j$ (0.0001-0.07)		Varying	Yes; Retain if value for children is <b>less</b> than value for adults.	No	12–14		
Protection Parameters							
Protection from reinfection L <sub>S</sub> , L <sub>F</sub> , L <sub>0</sub> , R	-	$p_R$	(0.60–0.85)	Varying	No	No	10,11,15–17
Access-to-care parameter	-	$p_E$	(0–1)	Varying	No	No	Assumed

#### 2.2 Operationalising age varying parameters

We assume that aspects of tuberculosis natural history and mortality vary by age. This is implemented by stratifying certain natural history parameters by age and applying age-specific prior ranges and relative constraints during calibration.<sup>18</sup> The following table describes the method used to operationalise the age varying differences in parameters between adults, defined as all ages greater than and equal to 15, and children, defined as all ages less than 15. For the rate per year of reactivation, relapse, and fast progression to tuberculosis disease, we assume that the rate for children is less than that for adults. For mortality rates, we assume the opposite: the rate for children is higher than that for adults.

Parameter Range		Age Varying Description	Age Scaling Parameter	Adults ( $ heta_{A15}$ )	Children ( $\theta_{A0}$ )
$\theta_j$ Rate per year of fast progression	(0.0696 - 0.111)	Retain if value for children is <b>less</b> than value for adults	Sample $j_1$ from $(0-1)$	Sample $ heta_{A15  ext{from}}$ (0.0696–0.111)	$\max(0.0696, \theta_{A15} \times j_1)$
$\sigma_j$ Rate per year of reactivation	(0.000135-0.00113)	Retain if value for children is <b>less</b> than value for adults	Sample $j_2$ from $(0-1)$	Sample $\sigma_{A15}$ from $(0.000135 - 0.00113)$	$\max(0.000135, \sigma_{A15} \times j_2)$
$ ho_j$ Rate per year of relapse	(0.01 – 0.07)	Retain if value for children is <b>less</b> than value for adults	Sample $j_3$ from $(0-1)$	Sample $ ho_{A15}$ from $\left(0.010.07 ight)$	$\max(0.01, \rho_{A15} \times j_3)$
$\mu_{DC_j}$ Clinical TB mortality rate per year	(0-0.178)	Retain if value for children is <b>greater</b> than value for adults	$\begin{array}{c} \text{Sample } S_{Age} \\ \text{from } (01) \end{array}$	$\mu_{DC_{A0}} \times S_{Age}$	Sample $\mu_{DC_{A0}}$ from $(0{-}0.178)$
$\mu_{T_j} = \frac{\kappa_j}{\tau}$ On-treatment mortality rate per year	(0-0.270)	Retain if value for children is <b>greater</b> than value for adults	$\frac{\text{Sample }S_{Age}}{\text{from }(01)}$	$rac{\kappa_{A0}}{ au}  imes S_{Age}$	Sample $\kappa_{A0}$ from $\left(00.135 ight)$

Table S2.2How age varying parameters are operationalized

#### 2.3 Treatment initiation and outcomes

Steps for calculating treatment initiation, treatment completion, non-completion, and mortality rates are described in the Supplementary Material for Clark et. al.<sup>1</sup> We assume the SFR is the ratio between treatment completions to the sum of treatment completions and non-completions. In India, SFR = 0.96. The data used to calculate the on-treatment outcomes was obtained from the WHO. However, as the private sector accounts for a substantial portion of treatments in India, and not all of the treatments conducted in the private sector are reported, we make adjustments to the on-treatment completion and non-completion fractions from Table S2.3 as described below and in Table S2.4.

#### Table S2.3 Calculating treatment outcome parameter values for adults and children

Parameter	Adults	Children
$\kappa_j$ On-treatment mortality fraction	$\kappa_{A0}  imes S_{Age}$	Sample $\kappa_{A0}$ from $(0-0.135)$
$S_j$ On-treatment completion fraction	$(1 - \kappa_{A15})$ SFR	$(1 - \kappa_{A0})$ SFR
$f_j$ On-treatment non-completion fraction	$(1 - \kappa_{A15})(1 - \mathrm{SFR})$	$(1-\kappa_{A0})(1-{ m SFR})$

We assume that the total number of treatments is composed of the treatments that are reported and the treatments that are not reported. We assume that the on-treatment mortality fraction is the same in the public and private sector, but want to adjust the treatment completion and non-completion rates to account for differences between those reported and those not reported as in Table S2.4.

es for India by year

Description	Symbol			Year $(k)$						
Description	Symbol	≤2012	2013	2014	2015	2016	2017	2018	2019	≥2020
Fraction of total treatments reported	$f_{T,k}$	0.60	0.63	0.68	0.67	0.73	0.77	0.80	0.83	0.87
On-treatment mortality rate	$rac{\kappa_j}{ au}$	$\frac{\kappa_j}{\tau}$ Sample $\kappa_{A0}$ from (0, 0.135), then $\kappa_{A15} = \kappa_{A0} \times S_{Age}$								
On-treatment completion rate	$\frac{s_j}{\tau}$	$\frac{f_{T,k}0.96(1-\kappa_j) + (1-f_{T,k})0.40}{\tau}$								
On-treatment non- completion rate	$\frac{f_j}{\tau}$	$\frac{f_{T,k}0.04(1-\kappa_j) + (1-f_{T,k})(0.60-\kappa_j)}{\tau}$								

We assume that 60% of the total treatment occurs in the public sector and the remaining 40% occurs in the private sector. We assume that all treatments not reported are from the private sector, that the treatment completion rate in the private sector is 40%, and that there is no reporting bias (in that they were equally likely to not report treatment completions or non-completions or deaths). Before 2012, only the treatment conducted in the public sector was reported, but since then, treatment in the private sector has begun to be reported.<sup>19</sup>

#### 3. Model simulation and calibration

#### 3.1 Model simulation

We specified a system of ordinary differential equations defining the derivatives with respect to time of a set of state variables, to simulate the country-specific tuberculosis epidemic between 1900 and 2050. We initialised the simulation by distributing the population between the eight tuberculosis natural history states using a fitted parameter representing the proportion of the population uninfected at the start of the simulation. For each year of the simulation (1900–2050), our models are designed to exactly match the age and country-specific UN population estimates and projections. Forty percent of the population was assigned to the low access-to-care stratum and the remaining sixty percent of the population was assigned to the high access-to-care stratum.

#### 3.2 Model calibration

For this India modelling analysis, we followed the same modelling approach as in Clark et al.<sup>1</sup>

Broadly, this was as follows:

- 1. Construct a mechanistic model
- 2. Calibrate the model by identifying areas of the input parameter space where the output of the mechanistic model was consistent with the historical epidemiologic data
- 3. Use the calibrated model to simulate and predict future tuberculosis epidemiology and model new vaccines

In the context of this analysis, step 1 was achieved by creating the compartment differential equation model as specified in Section 1. For step 2, we independently calibrated a model by identifying areas of the parameter space that made the output of the model match the corresponding calibration targets (Table S3.1 below). Further details on the sources for the calibration targets and any additional modifications are in the subsequent sections.

The model was fitted to the calibration targets using history matching with emulation, a method that allows us to explore high-dimensional parameter spaces efficiently and robustly.<sup>20–23</sup> History matching progresses as a series of iterations, called waves, where implausible areas of the parameter space, i.e., areas that are unable to give a match between the model output (e.g., the predicted incidence rate by the model) and the empirical data (e.g., the incidence rate calibration target from the WHO data), are found and discarded. In order to identify implausible parameter sets, emulators, which are statistical approximations of model outputs that are built using a modest number of model runs, are used. Emulators provide an estimate of the value of the model at any parameter set of interest, with the advantage that they are orders of magnitude faster than the model.

History matching with emulation, implemented through the *hmer* package in R,<sup>24,25</sup> considerably reduced the size of the parameter space to investigate. Rejection sampling was then performed on the reduced space to identify at least 1000 parameter sets that matched all targets.

If we were unable to find at least 1000 fully fitted parameter sets using history matching with emulation, we subsequently used an Approximate Bayesian Computation using Markov Chain Monte Carlo method (ABC-MCMC). ABC-MCMC was conducted using the *easyABC* package in R, modified by the Sebastian Funk, Gwenan Knight, and the Tuberculosis Modelling group at LSHTM for adaptive sampling and to accept seeded parameter values.<sup>26,27</sup> We used parameter sets with the maximum number of targets fitted using history matching with emulation as starting seeds for multiple MCMC chains per country, with the ABC-MCMC algorithm continuously adapting using the last 1000 points, a burn in of 1000 samples, and the noise factor set to 0.0001.

Once we had obtained 1000 parameter sets that produced output consistent with the calibration targets, we used those parameter sets with the mechanistic model to simulate the future (step 3) for each country.

Calibration Targets	Year	Age (years)	Estimate	Lower	Upper
	2000 <sup>28</sup>	All	289	149	473
		All	188	129	257
Tuberculosis incidence rate (per 100,000 population/year)	2020 <sup>28</sup>	0-14	91	56	126
		≥15	224	138	310
	2025 <sup>29</sup>	All	212	145	293
	20006	All	67	57	79
Tuberculosis mortality rate (per 100,000 population/year)	20206	All	37	34	40
	2025 <sup>29</sup>	All	36	33	39
	2000 <sup>2,7</sup>	All	177	142	212
Tuberculosis case notification rate	2020 <sup>2,7</sup>	All	136	109	163
(per 100,000 population/year)		0-14	33	26	40
		≥15	173	138	208
	2015 <sup>30,31</sup>	All	315	210	529
Active tuberculosis prevalence (per 100,000 population)	202132	All	312	218	406
	202132	≥15	394	276	512
Tuberculosis infection prevalence proportion	2021 <sup>32</sup>	All	0.314	0.114	0.514
Access-to-care tuberculosis prevalence ratio	202033	All	0.427	0.327	0.527
Subclinical tuberculosis prevalence ratio	202034	All	0.504	0.361	0.797
Proportion of incident tuberculosis cases having previously been treated	2020	All	0.191	0.139	0.241

#### Table S3.1India national model calibration targets

#### 3.3 Incorporating the COVID-19 pandemic

It will be a number of years before the full implications of disruptions to tuberculosis prevention and care during the COVID-19 pandemic are realised. The WHO provided estimates for the impact on the tuberculosis incidence and mortality rates between 2020–2025 relative to January 2020, shown in Figure S3.2.<sup>29</sup>

In order to ensure that the model is appropriately representing the future trends in incidence and mortality, we calibrated to the projected incidence and mortality for 2025, which is estimated as a 10% increase in both mortality and incidence in 2025 compared to January 2020. To implement this, we calculated a 10% increase to the incidence and mortality rates estimated by the WHO in 2019, shown in Table S3.2, and calibrated to both for 2025.



Figure S3.2 The estimated impact of the COVID-19 pandemic on the (A) tuberculosis incidence and (B) mortality rates from the WHO Global Tuberculosis Report 2021<sup>29</sup>

#### Table S3.2Incidence and mortality rate targets for all ages for 2025

Year	Incidence rate (per 100,000)	Mortality rate (per 100,000)
2019	193 (126–260)	33 (30–35)
2025 (10% increase from 2019)	212 (145–293)	36 (33–39)

A–Impact on tuberculosis incidence rate

**B**–Impact on tuberculosis mortality rate

#### **3.4** Modifications to calibration targets

#### **3.4.1** Tuberculosis prevalence targets

#### *i.* Adjusting the 2015 target bounds

We obtained an estimate for the tuberculosis prevalence in 2015 from "Estimating tuberculosis incidence from primary survey data: a mathematical modelling approach" by Pandey et al 2017.<sup>30</sup> In it, they estimate the prevalence of smear-positive cases across all ages in India, as well as the proportion of cases that are smear-positive. The mean and 95% confidence intervals for the estimates of these are 159.38 (122.9–196.59) and 0.63 (0.43–0.93) respectively.<sup>30</sup> Cited sources within the paper suggest that these quantities have been modelled as lognormal (smear-positive prevalence) and beta (smear-positive proportion) distributed.<sup>30</sup> The total prevalence, therefore, can be determined as

Pulmonary tuberculosis prevalence =  $\frac{\text{Smear-positive prevalence}}{\text{Smear-positive proportion}}$ 

If we assume that the mean estimate for the proportion of cases that are smear-positive is accurate, then we simply quotient the smear-positive bounds by this value (0.63). This gives

Pulmonary tuberculosis prevalence = 
$$253.0$$
 (195.1–312.0)

Since we have confidence intervals and a knowledge of the underlying distributions, we can attempt to determine the hyperparameters of the distributions. Once we have these, we can sample repeatedly from the quotient of the two distributions to get an estimate for its confidence interval. We sample from the numerator's distribution, sample from the denominator's distribution, and quotient them to represent a sample from the (unknown) prevalence distribution. Given enough samples, we can obtain a reasonable estimate of the confidence interval. Since the lognormal distribution has a closed-form, we can simply solve for the hyperparameters.

Smear-positive prevalence 
$$\sim \text{lognorm}(\mu = 5.046, \sigma^2 = 0.01436)$$

The beta-distribution is less straightforward, but we can use maximum likelihood estimation to find feasible parameter values. Doing so gives

Smear-positive proportion 
$$\sim beta(\alpha = 10, \beta = 6)$$

Then we perform monte-carlo sampling to generate a representative sample from our quotient distribution, from which we obtain a 95% confidence interval.

Pulmonary tuberculosis prevalence = 253.0 (169.3–424.7)

#### *ii.* Adjusting for extrapulmonary tuberculosis

In our model we are representing everyone with tuberculosis, which includes both pulmonary (PTB) and extrapulmonary tuberculosis (EPTB). EPTB is not infectious but is included in the WHO estimates of yearly incidence and mortality rates. The 2021 prevalence estimates from the National Tuberculosis Prevalence Survey did not adjust for EPTB in the estimate provided for adults, and neither did the 2015 study which estimated the tuberculosis prevalence from subnational surveys. Therefore, we want to adjust the PTB prevalence estimates and range by the amount of EPTB in order to estimate the total TB prevalence. To estimate the proportion of EPTB, we used the average of the proportion of incident extrapulmonary tuberculosis cases from 2013–2020 (Table S3.3).

Year	New EPTB cases	Relapse EPTB cases	Total incident EPTB cases	Total incident cases	Proportion incident EPTB cases
2013	226,557	_	226,557	1,243,905	0.18
2014	275,502	_	275,502	1,609,547	0.17
2015	298,831	—	298,831	1,667,136	0.18
2016	281,162	_	281,162	1,763,876	0.16
2017	276,786	3,067	279,853	1,649,694	0.17
2018	380,904	5,622	386,526	1,908,683	0.20
2019	476051	3,862	479,913	2,162,323	0.22
2020	471,000	4,034	475,034	1,629,301	0.29

 Table S3.3
 Number of incident tuberculosis cases by year in India

*Abbreviations: EPTB* = *extrapulmonary tuberculosis* 

From the National tuberculosis prevalence survey India 2019–2021, the prevalence of microbiologically confirmed pulmonary tuberculosis among population aged  $\geq 15$  years in India was estimated at 316 (290–342) [This adjusted prevalence was estimated using a robust standard errors model with imputation and inverse probability weighting].<sup>32</sup> Averaging the proportion of incident EPTB cases column in Table S3.3 and dividing the estimates and bounds on the pulmonary tuberculosis prevalence estimates by (1- average of proportion of incident EPTB cases) we obtain the following as the estimates of the tuberculosis prevalence per 100,000 population:

All ages tuberculosis prevalence in 2015 = 315.1 (210.8–529.0)

Adult tuberculosis prevalence in 2021 = 393.6 (361.2–426.0)

#### iii. Adjusting the 2021 target bounds

The National Tuberculosis Prevalence Survey India 2019–2021 reports estimates for the prevalence of all forms of tuberculosis among all age groups in India (312.0 [286.0–337.0] per 100,000 population) and the prevalence of microbiologically confirmed pulmonary tuberculosis among adults aged  $\geq 15$  years in India (316.0 [290.0–342.0] per 100,000 population). As described in the previous section, we adjusted the estimate of the prevalence of pulmonary tuberculosis in adults for EPTB, giving a revised estimate for the prevalence of all forms of tuberculosis disease in adults of 393.6 (361.2–426.0). We subsequently increased the upper and lower bounds on the all age and adult targets by 30%, leading to estimates of 312.0 (218.4–405.6) and 393.6 (275.5–511.7) respectively. Rationale for adjusting the bounds on the targets is described below.

#### Rationale 1: Impact of the Covid-19 pandemic

Some state groups started and completed the survey before the COVID-19 pandemic, others during, others after the major pandemic waves had completed.<sup>32</sup> Depending on the impact of COVID-19 measures on tuberculosis, this could bias the estimates of the region either up or down, and bias the overall estimate of the tuberculosis prevalence for India, particularly as Delhi (the region with the highest estimated tuberculosis prevalence) started and completed the survey before the pandemic.<sup>32</sup>

#### Rationale 2: Differences between planned surveyed clusters and actual surveyed clusters

The National Tuberculosis Prevalence Survey India 2019–2021 compares the number of pulmonary tuberculosis cases notified at the state group level in 2019, 2020 and 2021 between those clusters who were surveyed and those who were not surveyed.<sup>32</sup> Although no statistically significant differences were observed between the surveyed and not-surveyed clusters, there are qualitative differences between the number of notifications of pulmonary tuberculosis between groups, where non-surveyed clusters consistently have a lower number of notifications.<sup>32</sup>

#### 3.4.2 Tuberculosis infection prevalence

#### *i.* Adjusting the 2021 target bounds

The National Tuberculosis Prevalence Survey India 2019–2021 reports an estimate for the prevalence of tuberculosis infection in India among adults of 0.314 (0.272-0.353). We adjusted the bounds to give a revised estimate of 0.314 (0.114-0.514), with rationale described below.

#### Rationale 1: Oversampling from Gujarat with no adjustment

Of the 55 clusters where IGRA testing was done, 31 were in Gujarat and 24 were in the remaining 19 state groups. Gujarat had the lowest estimated tuberculosis prevalence per 100,000 population.<sup>32</sup> If we assume that prevalence of tuberculosis infection is correlated with prevalence of tuberculosis disease, then we would anticipate that the tuberculosis infection prevalence estimates from Gujarat would be commensurately low. As more than half of the clusters were from Gujarat, and there is no indication of adjustment for oversampling from this region, it is possible that the reported country-level tuberculosis infection prevalence is an underestimate. If our assumption that prevalence of infection correlates with prevalence of disease was incorrect, the tuberculosis infection prevalence estimates may actually be overestimated. As such, we have adjusted the bounds to account for oversampling with no adjustment, but retained the central estimate, resulting in a calibration target of 0.314 (0.114–0.514).

#### 3.4.3 Tuberculosis case notifications

#### *i.* Adjusting to account for the private sector contribution to reported case notifications

Treatment in India can occur in the public or private sector. While this varies by state, it is estimated that 60% of treatment is performed in the public sector, and the remaining 40% in the private sector. According to the WHO Global TB Report 2019, reported case notifications only included notifications from the public sector before 2013.<sup>19</sup> From 2013-2020, reported case notifications began to include the private sector (Figure S3.4). By 2020, approximately 31% of the total reported notifications were from the private sector.<sup>19</sup>



### Figure S3.4 Contribution of the private sector to reported case notifications from WHO Global TB Report 2021<sup>29</sup>

The model represents case notifications as the number of tuberculosis treatment initiations. We want to calibrate the model to the *true* number of treatment initiations, as this is what the model will represent. Therefore, this involves adjusting the WHO reported case notifications to reflect underreporting from the private sector. To do this, we must calculate the fraction of total cases notifications (treatment initiations) that are reported, while accounting for both the private and public sector.

$$\begin{split} RN_{Total} &= Total \ Reported \ Notifications \\ RN_{Public} &= Public \ Sector \ Reported \ Notifications \\ RN_{Private} &= Private \ Sector \ Reported \ Notifications \\ RN_{Total} &= RN_{Public} + RN_{Private} \end{split}$$

Let:  $f_{\text{Private}} = \frac{\text{RN}_{\text{Private}}}{\text{RN}_{\text{Total}}}$  be the fraction of reported notifications that come from the private sector

Using the percent contribution of the private sector to the reported treatments, and the assumption that *all* treatments occurring in the public sector are reported, we can calculate the fraction of total notifications that are actually reported.

 $\begin{array}{l} N_{Total} = Total \ Notifications \\ N_{Public} = Public \ Sector \ Notifications \\ N_{Private} = Private \ Sector \ Notifications \\ N_{Total} = N_{Public} + N_{Private} \end{array}$ 

Let:  $r_{f,k} = \frac{\text{RN}_{\text{Private}}}{\text{N}_{\text{Private}}}$  be the fraction of total private sector notifications reported in year k

 $\operatorname{RN}_{\operatorname{Total}} = \operatorname{N}_{\operatorname{Public}} + r_{f,k} \times \operatorname{N}_{\operatorname{Private}}$ (1)

 $f_{\text{Private}} \times \text{RN}_{\text{Total}} = r_{f,k} \times \text{N}_{\text{Private}}$  (2)

 $\mathrm{RN}_{\mathrm{Total}} = \frac{r_{f,k} \times \mathrm{N}_{\mathrm{Private}}}{f_{\mathrm{Private}}} \quad (3)$ 

Sub (3) into (1)

 $\frac{r_{f,k} \times \mathbf{N}_{\mathrm{Private}}}{f_{\mathrm{Private}}} = \mathbf{N}_{\mathrm{Public}} + r_{f,k} \times \mathbf{N}_{\mathrm{Private}}$ 

Solve for  $r_{f,k}$ 

$$r_{f,k} = \frac{N_{\text{Public}}}{N_{\text{Private}}(\frac{1}{f_{\text{Private}}} - 1)}$$
$$\therefore r_{f,k} = \frac{60}{40(\frac{1}{f_{\text{Private}}} - 1)}$$

Note: This calculation is valid for  $f_{Private} > 0$ 

We want to calculate  $f_T$  = fraction of total notifications reported

$$f_T = \frac{\text{RN}_{\text{Total}}}{\text{N}_{\text{Total}}}$$
$$f_T = \frac{\text{RN}_{\text{Public}} + \text{RN}_{\text{Private}}}{\text{N}_{\text{Total}}}$$

Assume:

 $RN_{Public} = N_{Public} = 60$ 

 $N_{\rm Total} = 100$ 

$$f_T = \frac{60 + r_{f,k} \times N_{\text{Private}}}{100}$$

Using the derived equation, we can calculate the fraction of total notifications reported from 2013–2020 (Table S3.4).

Year (k)	Fraction of reported notifications that came from the private sector $f_{\mathrm{Private},k}$	Fraction of total possible private sector notifications that were reported $T_{f,k}$	Fraction of total notifications reported $f_{T,k}$
≤ 2012	0	0	0.60
2013	0.05	0.08	0.63
2014	0.12	0.20	0.68
2015	0.10	0.17	0.67
2016	0.18	0.33	0.73
2017	0.22	0.42	0.77
2018	0.25	0.50	0.80
2019	0.28	0.58	0.83
2020	0.31	0.674	0.87

## Table S3.4The fraction of tuberculosis treatment notifications in India from the private sector and<br/>overall

To adjust the WHO reported case notification estimates for underreporting, we divide the estimates by the fraction of total treatments reported ( $f_T$ ), and assume 20% upper and lower uncertainty bounds. The reported and adjusted estimates of case notifications are provided in Table S3.5 and assume 20% upper and lower uncertainty bounds. The reported and adjusted estimates of case notifications are provided in Table S3.5.

#### Table S3.5 The WHO reported and adjusted tuberculosis case notification targets for India

Year	WHO reported case notification value	Adjusted case notification value	<b>Low bound</b> (Adjusted value $\times$ 0.8)	High bound (Adjusted value $\times$ 1.2)
2000	106	177	142	212
2020	118	136	109	163

#### 3.4.4 Proportion of previously treated incident cases

#### *i.* Adjusting the proportion retreated bounds

The proportion retreated target is included to ensure that the disease tuberculosis incidence is derived from the correct source (i.e., to ensure that we do not overestimate the amount of incidence that is coming from fast-progression or reactivation without treatment).

The data available from the WHO are:

- 1. Number of case notifications (i.e., the notified treatment initiations), per year
- 2. Number of case notifications who are people who have been previously treated, per year

By dividing the number of notifications who are people who have been previously treated (2) by the total number of notifications (1), we get the proportion of notifications that have been previously treated.

 $= \frac{\text{Number of notifications who are people who have been previously treated per year}}{\text{Number of notifications per year}}$ 

= Proportion of notifications that have been previously treated

We assume that at equilibrium, the proportion of notifications who have been previously treated will be equal to the proportion of incident disease cases who have been treated previously.

The estimate of the proportion of notifications that have been previously treated for India from the WHO dataset is 10.0% (4.3–14.7). However, country specific estimates may be subject to recall bias as they rely on patients to accurately report previous treatment. Additionally, studies have shown that approximately 11% of patients recorded as "new" have had some form of previous tuberculosis treatment.<sup>35</sup> Therefore, we adjusted the estimates from the WHO dataset, and calibrated to a target of 19.1% (13.9–24.1).

#### *ii.* Calculating the proportion retreated target in the model

The subsequent pages describe the methods used to calculate the proportion retreated target.

**Definition 1:** The number of notifications, per year is the flow from Dc and  $T = \eta \times D_C$ 

**Definition 2:** Being "previously treated" implies that an individual arrived in the R compartment via the T compartment.

**Definition 3:** For an individual to count as a notification of a person who was previously treated (Definition 2), they must flow from  $T \rightarrow R \rightarrow Ds \rightarrow Dc \rightarrow T$ 

Looking at the total number of notifications broken down to their origins, we see that:

Total number of notifications per year =

Number of notifications of people who were in Ls per year

- + Number of notifications of people who were in Lf per year
- + Number of notifications of people who were in R per year

The "Notifications of people who were in R" term is further broken down into:

- People who entered R from T, per year
- People who entered R from Dc, per year
- People who entered R from Ds, per year

We can rewrite the total number of notifications per year equation as:

Total number of notifications per year =

Number of notifications of people who were in Ls per year

- + Number of notifications of people who were in Lf per year
- + Number of notifications of people who were in R having entered R from Ds per year
- + Number of notifications of people who were in R having entered R from Dc per year
- + Number of notifications of people who were in R having entered R from T per year

Recall now what we are looking to calibrate to:

 $= \frac{\text{Number of notifications who are people who have been previously treated per year}}{\text{Number of notifications per year}}$ 

The denominator is directly available from the model: the total number of notifications ( $\eta \times D_C$ ). Using definitions 2 and 3 above, the "number of notifications who are people who have been previously treated per year" = "notifications of people who were in R having entered R from T per year". Therefore, we can redefine our calibration target as:

 $= \frac{\text{Number of notifications of people who were in R having entered R from T per year}{\text{Total number of notifications per year}}$ 

We do not have **notifications** disaggregated by source, but we do have **incidence** disaggregated by source. Incident cases are defined as the flow into Ds, which can be from R, from Ls, or from Lf.

Total number of incident cases per year = Total number of incident cases of people from Lf per year + Total number of incident cases of people from Ls per year + Total number of incident cases of people from R per year

We obtain output on all of these flows, so we can calculate the proportion of incident cases from each pathway (Lf, Ls, and R) easily by just dividing the total number of incident cases of people from Lf, Ls or R by the total number of incident cases.

The proportions of incidence from each pathway are:

 $\frac{RD}{(RD + LsD + LfD)} \qquad \qquad \frac{LfD}{(RD + LsD + LfD)} \qquad \qquad \frac{LsD}{(RD + LsD + LfD)}$ 

RD = flow from R to Ds = total number of incident cases of people from R, per year LsD = flow from Ls to Ds = total number of incident cases of people from Ls, per year LfD = flow from Lf to Ds = total number of incident cases of people from Lf, per year RD + LsD + LfD = total number of incident cases, per year

Similarly, we can disaggregate the flow from R to Ds further into how the people in R entered R.

Total number of incident cases of people from R per year = Total number of incident cases of people from R who entered R from T per year + Total number of incident cases of people from R who entered R from Dc per year + Total number of incident cases of people from R who entered R from Ds per year

Again, we don't have information on the disaggregated numbers of incident cases from R based on how they entered R, but we do have information on the entry to R.

Total number entering into R per year = Total number entering R from T per year + Total number entering R from Ds per year + Total number entering R from Dc per year

The proportion of the total flow into R from each of T, Ds, and Dc per year is:

 $\frac{\mathrm{TR}}{(\mathrm{TR}+\,\mathrm{DsR}\,+\,\mathrm{DcR})} \qquad \qquad \frac{\mathrm{DsR}}{(\mathrm{TR}+\,\mathrm{DsR}\,+\,\mathrm{DcR})} \qquad \frac{\mathrm{DcR}}{(\mathrm{TR}+\,\mathrm{DsR}\,+\,\mathrm{DcR})}$ 

TR = flow from T to R = total number entering R from T per year DcR = flow from Dc to R = total number entering R from Dc per year DsR = flow from Ds to R = total number entering R from Ds per year TR + DsR + DcR = total number entering R per year If we assume that the flows **INTO** R from each of T, Ds, and Dc are in the same proportions as the flows **OUT** of R, then we can disaggregate the outflow from R (which is the number of incident cases of people from R, per year, we called RD in the equation above) into incident cases of people from R who entered R from each of T, Ds, and Dc, per year by multiplying RD by the proportion from each of T, Ds, and Dc

Number of incident cases of people from R who entered R from T, per year

= (Number of incident cases of people from R, per year)(Proportion of flow out of R that is from people who entered R from T, per year) etc.

We can rewrite RD in terms of the disaggregated pathways from T, Ds, and Dc:

$$RD = RD \times \frac{TR}{(TR + DsR + DcR)} + RD \times \frac{DsR}{(TR + DsR + DcR)} + RD \times \frac{DcR}{(TR + DsR + DcR)}$$

Subbing in the expression for RD above into the equation for the proportion of incident cases from R, we obtain:

$$\frac{\text{RD} \times \frac{\text{TR}}{(\text{TR} + \text{DsR} + \text{DcR})} + \text{RD} \times \frac{\text{DsR}}{(\text{TR} + \text{DsR} + \text{DcR})} + \text{RD} \times \frac{\text{DcR}}{(\text{TR} + \text{DsR} + \text{DcR})}}{(\text{RD} + \text{LsD} + \text{LfD})}$$

Factor, simplify and rewrite:

$$= \frac{\text{RD}}{(\text{RD} + \text{LsD} + \text{LfD})} * \left(\frac{\text{TR}}{(\text{TR} + \text{DsR} + \text{DcR})} + \frac{\text{DsR}}{(\text{TR} + \text{DsR} + \text{DcR})} + \frac{\text{DcR}}{(\text{TR} + \text{DsR} + \text{DcR})}\right)$$
$$= \left[\frac{\text{RD}}{(\text{RD} + \text{LsD} + \text{LfD})}\right] \left[\frac{\text{TR}}{(\text{TR} + \text{DsR} + \text{DcR})}\right] + \left[\frac{\text{RD}}{(\text{RD} + \text{LsD} + \text{LfD})}\right] \left[\frac{\text{DsR}}{(\text{TR} + \text{DsR} + \text{DcR})}\right]$$
$$+ \left[\frac{\frac{\text{RD}}{(\text{RD} + \text{LsD} + \text{LfD})}\right] \left[\frac{\text{DcR}}{(\text{TR} + \text{DsR} + \text{DcR})}\right]$$

Proportion of incident cases from R =

(Proportion of incident cases from R who entered R from T)

+ (Proportion of incident cases from R who entered R from Dc)

+ (Proportion of incident cases from R who entered R from Ds)

The assumption we make here is that (at equilibrium) these proportions of incident cases will be equivalent for flows entering Ds (incident cases), entering Dc (progression from subclinical to clinical disease) and entering T (treatment initiation / case notifications).

$$\frac{RD}{(RD + LsD + LfD)} \frac{LfD}{(RD + LsD + LfD)} \frac{LsD}{(RD + LsD + LfD)}$$

$$\left[ \frac{RD}{(RD + LsD + LfD)} \right] \left[ \frac{TR}{(TR + DsR + DcR)} \right] \left[ \frac{RD}{(RD + LsD + LfD)} \right] \left[ \frac{DsR}{(TR + DsR + DcR)} \right]$$

$$\left[ \frac{RD}{(RD + LsD + LfD)} \right] \left[ \frac{DcR}{(TR + DsR + DcR)} \right]$$

Therefore, the proportion of notifications of people who were in R having entered R from T will be the same as the proportion of incidence from people who were in R having entered R from T.

Going back to the calibration target once again:

$$= \frac{\text{Number of notifications of people who were in R having entered R from T per year}}{\text{Total number of notifications per year}}$$

Although we do not know the number of notifications of people who were in R having entered R from T per year, this is equal to the proportion of notifications of people who were in R having entered R from T multiplied by the total number of notifications per year

 $= \frac{\text{Total number of notifications per year} \times \text{Proportion of notifications of people who were in R having entered R from T}{\text{Total number of notifications per year}}$ 

We can cancel out the total number of notifications as it is in both the numerator and denominator.

= Total number of notifications per year × Proportion of notifications of people who were in R having entered R from T Total number of notifications per year

= Proportion of notifications of people who were in R having entered R from T

This value is calculated as the proportion of notifications of people who were in R multiplied by the proportion of the entry into R that came from T

$$= [\frac{\mathrm{RD}}{(\mathrm{RD} + \mathrm{LsD} + \mathrm{LfD})}][\frac{\mathrm{TR}}{(\mathrm{TR} + \mathrm{DcR} + \mathrm{DsR})}]$$

However, there may be some people who recently entered R from Dc or Ds, but who had also previously had treatment. Therefore, the previous equation is revised as:

 $= \left[\frac{\text{RD}}{(\text{RD} + \text{LsD} + \text{LfD})}\right] \left[\frac{\text{TR} + (\text{DcR} + \text{DsR}) \times (\text{proportion of those in (DcR} + \text{DsR}) \text{ who have been treated previously}}{(\text{TR} + \text{DcR} + \text{DsR})}\right]$ 

We assume that the proportion of those in (DcR + DsR) who have been treated previously is the same as the proportion of those in DsR who have been treated previously. We can then set the value:

proportion of those in (DcR + DsR) who have been treated previously =

 $[\frac{RD}{(RD + LsD + LfD)}][\frac{TR + (DcR + DsR) \times (proportion of those in (DcR + DsR) who have been treated previously}{(TR + DcR + DsR)}]$ 

If we substitute in the term, we can see that the same term is repeated again and again. Let

$$A = \frac{RD}{(RD + LsD + LfD)(TR + DcR + DsR)}$$

Then we can rewrite the above as:

A[TR + (Ds + Dc)]A[TR + (Ds+Dc)]A[...]]

Let B = TR and C = (Ds + Dc), substitute and expand:

$$A[B + C(A[B + C(A[...]))]$$

$$AB + AC(AB + AC(AB[...]))$$

Let X = AB and Y = AC, substitute and expand:

$$= X + Y(X + Y(X|...|))$$
$$= X + XY + XY2 + XY3 ...$$
$$= X (1 + Y + Y2 + Y3 ...)$$
$$= \frac{X}{(1-Y)}$$

Substituting back in for X, Y, A, B, and C we obtain:

$$= \frac{AB}{(1-AC)}$$
$$= \frac{\frac{RD}{(RD + LsD + LfD)(TR + DcR + DsR)} \times TR}{(1 - \frac{RD}{(RD + LsD + LfD)(TR + DcR + DsR)} \times (DcR + DsR))}$$

 $=\frac{\mathrm{RD}\times\mathrm{TR}}{(\mathrm{RD}+\mathrm{LsD}+\mathrm{LfD})(\mathrm{TR}+\mathrm{DcR}+\mathrm{DsR})-\mathrm{RD}(\mathrm{DcR}+\mathrm{DsR})}$ 

 $=\frac{RD\times TR}{TR(RD+LsD+LfD)+(DcR+DsR)(LsD+LfD)}$ 

RD = flow from R to Ds = total number of incident cases of people from R, per year TR = flow from T to R = total number entering R from T, per year RD + LsD + LfD = total number of incident cases, per year

DcR = flow from Dc to R = total number entering R from Dc, per yearDsR = flow from Ds to R = total number entering R from Ds, per yearLsD = flow from Ls to Ds = total number of incident cases of people from Ls, per yearLfD = flow from Lf to Ds = total number of incident cases of people from Lf, per year

#### 4. Policy scenarios

#### 4.1 No-new-vaccine baseline

The primary no-new-vaccine simulated was the no-new-vaccine baseline, which assumed non-vaccine tuberculosis interventions continue at current levels into the future. As reported country-level data includes the high coverage levels of neonatal BCG vaccination, this was not explicitly modelled. We assumed that BCG vaccination would not be discontinued over the model time horizon.

#### 4.2 Vaccine delivery scenarios

Two recently completed phase 2 trials have demonstrated encouraging efficacy results. The M72/AS01<sub>E</sub> candidate vaccine is a subunit vaccine for which results from a completed Phase IIb trial were published at the end of 2019.<sup>36</sup> After three years of follow-up, the efficacy of M72/AS01<sub>E</sub> at preventing disease in latently infected adults from South Africa, Zambia, and Kenya was estimated at 49.7% (95% confidence interval = 2.1-74.2).<sup>36</sup> To confirm this finding, a larger, Phase III follow-up study is needed, which includes participants who are uninfected, adolescents, as well as those living with HIV to assess safety and immunogenicity in these populations. This is being planned.

BCG-revaccination (administering a second dose of BCG to those who were vaccinated neonatally) was previously implemented in many countries, however evidence did not support the effectiveness of this practice. Interest in BCG-revaccination has recently been renewed following results from a trial for the vaccine candidate, H4:IC31. BCG-revaccination was assessed as a third parallel arm alongside H4:IC31 and a placebo in a pre-infection population in South Africa, and although neither vaccine appeared efficacious at preventing infection, BCG-revaccination appeared efficacious at preventing sustained infection (defined as three consecutive positive tests after day 84 of the trial) with an efficacy of 45.4% (6.4–68.1).<sup>37</sup> A larger trial of BCG-revaccination versus placebo in 1800 healthy adolescents from across South Africa is now underway to verify this finding.

We evaluated introducing vaccines with  $M72/AS01_E$  and BCG-revaccination characteristics compared to the no-new-vaccine baseline as described in the subsequent sections.

#### 4.2.1 Classifying tuberculosis vaccines

Before describing the specific characteristics for the vaccine scenarios that we investigated, we provide a brief overview on classifying tuberculosis vaccines (descriptions from Clark et al.<sup>1</sup>).

Tuberculosis vaccines are characterised on four key characteristics: the vaccine efficacy, the host infection status at the time of vaccination required for the vaccine to be efficacious, the mechanism of effect, and the duration of protection. Vaccine efficacy defines the magnitude of protection induced by the vaccine. Vaccine efficacy is assumed to be either "all or nothing", where the vaccine offers full protection to a subset of individuals (equal to the vaccine efficacy) who were vaccinated, or "degree", where the vaccine offers partial protection to all individuals who received the vaccine.

The host infection status at the time of vaccination required for the vaccine to be efficacious defines the *Mtb* infection status required of the population at the time they receive the vaccine for the vaccine to be efficacious. We divide the host infection status into No Current Infection (NCI), where the vaccine is efficacious in uninfected populations only, Current Infection (CI), meaning the vaccine is efficacious in populations with current infection with *Mtb* only, or Any Infection (AI) where the vaccine is efficacious in both pre- and post-infection populations.

The vaccine mechanism of effect type determines how the vaccine will offer protection. A prevention of infection (POI) vaccine protects individuals from initial or re-infection with *Mtb*, whereas a prevention of disease (POD) vaccine functions by preventing individuals who may be uninfected or infected with *Mtb* from progressing to active disease. A prevention of infection and disease vaccine (POI&D) prevents both infection and disease. Finally, the duration of protection represents the length of time following vaccination that individuals are protected.

#### 4.2.2 M72/AS01<sub>E</sub> and BCG-revaccination scenarios

For each vaccine product, we established one "Basecase" vaccine scenario based on clinical trial data and expert opinion. We then varied vaccine product and delivery scenarios as univariate scenario analyses from the Basecase scenario as described in Table S4.1.

	M72/AS01	l <sub>E</sub> vaccines	BCG-revaccir	ation vaccines	
Characteristic	Basecase Univariate scenario analyses		Basecase	Univariate scenario analyses	
Vaccine efficacy	50%	60%, 70%	45%	70%	
Duration of protection	10 years	5, 15, 20	10 years	5, 15, 20	
Infection status at time of vaccination required for vaccine to take	Any infection (current / no current infection)	Current infection only	No current infection only	Any infection (current / no current infection)	
Mechanism of effect	Prevents disease	Prevents infection and disease	Prevents infection	Prevents infection and disease	
Introduction year (years of any repeat campaigns)	2030 (2040)	2036 (2046)	2025 (2035, 2045)	2031 (2041)	
Age targeting	Campaign for ages 16-34,	Older ages (campaign for ages 18-55)	Campaign for ages 11-18,	Older ages (campaign for ages 16-34, routine age 15)	
	Toutile age 15	Elderly ages (campaign for ages 60+, routine age 60)	Toutile age 10	Elderly ages: campaign for ages 60+, routine age 60	
Target coverage (with scale-up to coverage over 5- years)	Campaign = 70% / Routine = 80%	Campaign = 50% / Routine = 70% Campaign = 90% / Routine = 90%	80%	70% 90%	

#### Table S4.1 M72/AS01<sub>E</sub> and BCG-revaccination scenarios evaluated in the analysis

#### 4.2.3 Vaccine delivery assumptions

#### Vaccine eligible population

In our modelling, we assume that there is no pre-vaccination infection testing. Therefore, even if a vaccine is only effective when delivered to uninfected individuals at the time of vaccination, we assume that both uninfected and infected individuals will receive the vaccine, and only the uninfected individuals will receive protection. Our model structure allows for counting and tracking individuals who received the vaccine but do not receive any protection from it.

#### Efficacy

From trial data, the efficacy of M72/AS01<sub>E</sub> at preventing disease in latently infected adults was estimated at 49.7% (2.1-74.2).<sup>36</sup> Therefore, our Basecase vaccine efficacy was set at 50%, and based on expert opinion we evaluated 60% and 70% as scenario analyses. BCG-revaccination appeared efficacious at preventing *sustained* infection with an efficacy of 45.4% (6.4–68.1).<sup>37</sup> The Basecase efficacy was set to 45%, and 70% was evaluated in a scenario analysis.

#### **Protection from repeat vaccinations**

BCG-revaccination: No additional protection if a second or third vaccine is administered while currently protected from the first.

 $M72/AS01_E$ : Protection increases if a second or third vaccine is administered while currently protected by a first or second vaccine by (1-current protection) times vaccine efficacy, as in Table S4.2.

Number of vaccine courses currently protected by	nber of vaccine courses Basecase Basecase		Efficacy variation 2
One	50.0%	60.0%	70.0%
Two	75.0%	84.0%	91.0%
Three	87.5%	93.6%	97.3%

#### Table S4.2 Increase in protection for the number of vaccine courses

Note that the number of vaccine courses refers to the number of vaccine courses that the individual is *currently* protected by, not that they have ever a) received, or b) been protected by. For example, if someone receives one vaccine, then wanes, then receives another one, they would only be currently protected by one, <u>not two</u>, vaccines, and so the efficacy would be either 50%, 60%, or 70% depending on the scenario.

#### Mechanism of effect

We assume that a vaccine that protects against infection will work by reducing the rate of infection for both initial and re-infection, and that a vaccine that protects against progression to disease will work by reducing the rate of progression to subclinical disease. If the vaccine protects against both infection and disease we assume that it has the same efficacy against preventing disease as it does infection. For example, if the vaccine is defined as a prevention of infection and disease vaccine with 50% efficacy, it reduces the rate of infection by 50% and the rate of progression to disease by 50%.

#### Introduction year

The Basecase introduction years, 2025 and 2030 for BCG-revaccination and M72/AS01<sub>E</sub> respectively, were determined based on considering when new trial data would become available, as well as incorporating time for licensure and policy change. The introduction year considered in scenario analyses, 2031 and 2036 for BCG-revaccination and M72/AS01<sub>E</sub> respectively, was based on applying IAVI/Full Value Assessment of Tuberculosis Vaccines analyses from Shelly Malhotra and expert advice to the earliest possible introduction year.<sup>1</sup>

#### Age targeting

The Basecase age was informed by ages of trial participants and expert advice. Additional scenarios were informed by work conducted by Pelzer et. al and expert advice.<sup>38</sup>

#### 4.3 Vaccine model structure

Depending on the host infection status required at the time of vaccination for the vaccine to be efficacious, we implemented a different vaccine structure in the model to account for differences in Vaccinated Protected, Vaccinated Not Protected, and Vaccinated Waned. Each compartment in the vaccine structure is replicated for all tuberculosis natural history compartments, access-to-care strata, and ages.

#### 4.3.1 No Current Infection vaccines

A No Current Infection (NCI) vaccine requires an individual to be uninfected at the time of vaccination in order for the vaccine to be efficacious. Implementation in the TBVax model of an NCI vaccine with the possibility of two repeat vaccine courses is provided in Figure S4.1. For our purposes, we assume that the level of protection remains the same regardless of the number of vaccine courses received (i.e. level of protection in "Vaccinated Protected (one vaccine course)" is equal to "Vaccinated Protected (two vaccine courses)" etc.). Additionally, because the vaccine is only efficacious for NCI, and in this model once you leave  $U_N$  (the state where the vaccine is effective) you never return, once you enter a "Vaccinated Not Protected" state you *never* have the opportunity to become "Vaccinated Protected" again.



Figure S4.1 Vaccine structure for a NCI vaccine

#### 4.3.2 Current Infection vaccines

A Current Infection (CI) vaccine requires an individual to be infected at the time of vaccination in order for the vaccine to be efficacious. Implementation in the TBVax model of an CI vaccine with the possibility of two repeat vaccine courses is provided in Figure S4.2. For our purposes, we assume that the level of protection builds with each vaccine course, with efficacy values as in Table S4.2.



Figure S4.2 Vaccine structure for a CI vaccine (where protection builds with each vaccine course)

#### 4.3.3 Any Infection vaccines

An Any Current Infection (AI) vaccine will be efficacious with any infection status (aside from current active disease) at the time of vaccination. The "Vaccine Not Protected" compartments remain as we assume that individuals with subclinical disease may be accidentally vaccinated and would not receive protection from the vaccine. However, we do want to keep track of the number of vaccinations for cost purposes.

*AI-1 vaccines:* With each vaccine course the level of protection remains the same (Figure S4.3). Waning occurs from any of the Vaccinated Protected compartments to the Waned Protection compartment.





*AI-2 vaccines:* With each vaccine course the level of protection builds if the recipient is currently in a Vaccinated Protected compartment (Figure S4.4). This is the same structure as the CI vaccine with protection building (Figure S4.2). Waning occurs from any of the Vaccinated Protected compartments to the Vaccinated Protected compartment one level below, or to the Waned Protection compartment for those with only one course of protection.





#### 5. Economic analysis methods

Before undertaking this work, we established an economic analysis plan, involving stakeholders and government officials to ensure we had incorporated all necessary information and planned to report on all key outcomes, to outline the methods used in this work. This is summarised below.

#### 5.1 Calculation of disability-adjusted life years

We calculated the difference in total disability-adjusted life years (DALYs) from vaccine introduction to 2050 for each scenario compared to the no-new-vaccine baseline. We used the disability weight for tuberculosis disease from the Global Burden of Disease 2019 study,<sup>39</sup> and country- and age-specific life expectancy estimates from the United Nations Development Programme.<sup>40</sup> To incorporate parameter uncertainty in years lost due to disability (YLD) weight estimates, we made 1000 draws from disability weight uncertainty ranges.

#### 5.2 Tuberculosis-related cost model

We estimated health system unit costs, patient costs and productivity losses based on a scoping review of published literature. For the tuberculosis programme, we obtained unit costs for drug-susceptible (DS) and drug-resistant (DR) tuberculosis treatment and diagnostic costs. In India, as elsewhere,<sup>41,42</sup> we explicitly include a financial incentive paid to the private sector to encourage case notification. Uncertainty in cost estimates is characterised through gamma distributions around plausible unit cost estimates in a probabilistic sensitivity analysis. There was considerable uncertainty in the cost of delivering a vaccine, including the price of vaccine compounds and programmatic delivery among adolescents. Based on expert opinion from funders, for the M72/AS01<sub>E</sub> vaccine we assume a \$2.50 per-dose vaccination price with two doses per course assumed in the Basecase. Based on the average estimated BCG price from 2020–2023 from UNICEF,<sup>43</sup> the vaccine price per dose for BCG-revaccination was set at \$0.17, with one dose assumed per course.

#### 5.3 Vaccine introduction

Due to uncertainty in unit costs of vaccine supply and introduction among populations who may not typically receive large-scale mass vaccination, we make several assumptions around costs to supply and introduction of vaccines. One time vaccine introduction costs are assumed to be \$2.40 per recipient based on the GAVI VIG, with a further \$0.11 supply costs per recipient. We assume a 5% wastage rate. All cost inputs are given in Table S5.1 below.

#### 5.4 Cost-effectiveness analysis and willingness-to-pay thresholds

We calculated the incremental cost effectiveness ratio as the ratio between the incremental benefit, in DALYs averted, and the incremental cost, in USD, for each run across vaccination and baseline scenario. Both costs and benefits were discounted to 2025 (when vaccination began) at 3%, per guidelines.<sup>44</sup> We analysed cost-effectiveness by 2050, reflecting a 25-year timeframe in line with WHO END TB<sup>45</sup> and UN SDG TB control targets.<sup>46</sup> We measured cost-effectiveness by 2050 against three India specific cost thresholds: 1x gross domestic product (GDP) per-capita (US\$1,927.71), the Ochalek upper bound (US\$363), and the Ochalek lower bound (US\$264).<sup>47</sup>

	<b>TELL 1 1 1</b>				
Table S5.1	Tuberculosis testing,	diagnostic, a	and vaccination	related	cost inputs

Unit Cost	Estimate	Lower Bound	Upper Bound	Sources
Varying costs		*		
Unit cost of testing/diagnosis for DS cases	\$22.45	\$18.37	\$26.53	48
Unit cost of testing/diagnosis for DR cases	\$24.36	\$5.04	\$117.81	49
Unit cost of treatment for DS cases	\$317.00	\$254.00	\$374.00	50
Unit cost of treatment for DR cases	\$3,891.00	\$3,382.00	\$4,401.00	51
Non-medical patient cost per DS-TB disease episode (including transportation)	\$51.25	\$22.12	\$76.94	52,53
Indirect patient cost per DS-TB disease episode (time spent on treatment and transport * wage)	\$117.01	\$24.04	\$460.24	53,54
Non-medical patient cost per DR-TB disease episode (including transportation)	\$143.49	\$61.95	\$215.42	52,53
Indirect patient cost per DR TB disease episode (time spent on treatment and transport * wage)	\$327.63	\$67.30	\$1,288.66	53,54
Recurrent vaccine delivery cost	\$2.50	\$1.00	\$5.00	55
Fixed costs				
Incentive per patient treated in private sector	\$4.19			56,57
Patient nutritional support	\$7.87			57
Welfare payments to TB patient	\$30.35			57
M72/AS01 <sub>E</sub> price per dose (2 doses per course)	\$2.50			Expert opinion
BCG price per dose (1 dose per course)	\$0.17			43
One-time vaccine introduction costs per person	\$2.40			55
Vaccine supply costs	\$0.11			58

#### 6. Health impact outcomes

The following measures were calculated for each vaccine scenario as the median and 95% uncertainty range

- Percent incidence rate reduction in 2050 for each vaccine scenario compared to the estimated value in 2050 by *No-New-Vaccine* baseline
- Percent mortality rate reduction in 2050 for each vaccine scenario compared to the estimated value in 2050 by *No-New-Vaccine* baseline
- Cumulative cases averted for each vaccine scenario between vaccine introduction (either 2025 or 2030) and 2050 compared to the cumulative number of cases estimated by the *No-New-Vaccine* baseline between the corresponding years
- Cumulative deaths averted for each vaccine scenario between vaccine introduction (either 2025 or 2030) and 2050 compared to the cumulative number of cases estimated by the *No-New-Vaccine* baseline between the corresponding years
- Cumulative treatments averted for each vaccine scenario between vaccine introduction (either 2025 or 2030) and 2050 compared to the cumulative number of cases estimated by the *No-New-Vaccine* baseline between the corresponding years

#### SUPPLEMENTARY RESULTS

7. No-New-Vaccine baseline

#### 7.1 No-New-Vaccine baseline calibration



Figure S7.1 Tuberculosis incidence, disease prevalence, case notification and mortality rate trends from 2000–2050 for all ages



Figure S7.2 Tuberculosis infection prevalence, proportion retreated, access-to-care ratio and ratio of subclinical tuberculosis to total tuberculosis trends from 2000–2050 for all ages



Figure S7.3 Tuberculosis incidence and mortality rate trends from 2000–2050 by age group

The black trend line indicates the median modelled output with 95% uncertainty in shaded grey. The black dot and vertical line is the calibration target from Table S3.1.



Figure S7.4 Tuberculosis disease and infection prevalence trends from 2000–2050 by age group



Figure S7.5 Tuberculosis case notification and proportion retreated trends from 2000–2050 by age group



Figure S7.6 Access-to-care ratio and the ratio of subclinical tuberculosis to all active tuberculosis trends from 2000–2050 by age group

#### 7.2 Posteriors distributions for model parameters



Figure S7.7 Posterior distributions for the 1000 parameter sets of the 19 parameters varied during calibration

Definitions: chi = rate of natural cure, eta = rate of treatment initiation, j1A0 = age multiplier for rate of fast progression (theta), j2A0 = age multiplier for rate of reactivation (sigma), j3A0 = age multiplier for rate of relapse (rho), j4A0 = age multiplier for rate of treatment initiation, kappa = on-treatment mortality fraction, muDc = rate of clinical disease mortality, muK = rate of background mortality for increased mortality rate from the Recovered compartment, multiplier = the multiplier to see the initial distribution of the population into the natural history compartments, omegaS0 = rate of progression between Latent-Slow and Latent-Zero, pEhigh = multiplier for high access-to-care relative to low access-to-care, pR = protection from reinfection for those in the Latency or Recovered compartments, pT = rate of transmission, rho = rate of relapse, sageA15 = age multiplier for mortality rates, sigma = rate of reactivation, theta = rate of fast progression following infection, zeta = rate of progression from subclinical to clinical disease compartments.

#### 8. Health impact results

#### 8.1 M72/AS01<sub>E</sub> scenarios



Figure S8.1 Incidence and mortality rate reductions in 2050 for the M72/AS01<sub>E</sub> scenarios



## Figure S8.2 Cumulative tuberculosis cases, treatments, and deaths averted between 2030 and 2050 for the M72/AS01<sub>E</sub> scenarios

The horizontal line is the median value of the Basecase for each vaccine, and the vertical line separates vaccine profile and delivery scenarios.

Scenario	IRR in 2050 (%)	MRR in 2050 (%)	Cumulative cases averted 2030–2050	Cumulative treatments averted 2030–2050	Cumulative deaths averted 2030–2050
Basecase	30.9%	30.4%	12.7m	6.9m	2.0m
	(28.9–33.5)	(28.5–33.1)	(11.0–14.6)	(6.1–7.9)	(1.8–2.4)
60% efficacy	35.6%	35.1%	14.8m	8.0m	2.4m
	(33.3–38.5)	(33.0–38.0)	(12.8–17.0)	(7.1–9.2)	(2.1–2.8)
70% efficacy	39.8%	39.3%	16.8m	9.1m	2.7m
	(37.5–43.0)	(37.1–42.5)	(14.5–19.3)	(8.1–10.4)	(2.4–3.1)
5 years duration of protection	20.4%	20.9%	9.4m	5.1m	1.5m
	(18.9–22.5)	(19.4–22.9)	(8.1–10.9)	(4.6–6.0)	(1.4–1.8)
15 years duration of protection	36.0%	35.0%	14.3m	7.6m	2.3m
	(33.9–38.9)	(32.9–37.8)	(12.3–16.3)	(6.8–8.8)	(2.0–2.6)
20 years duration of protection	39.1%	37.7%	15.2m	8.1m	2.4m
	(36.9–42.1)	(35.5–40.6)	(13.1–17.3)	(7.2–9.3)	(2.1–2.8)
Prevention of infection and disease	39.7%	39.0%	16.2m	8.7m	2.6m
	(37.2–43.1)	(36.5–42.3)	(14.1–18.7)	(7.8–10.0)	(2.3–3.0)
Efficacious with current infection at vaccination	14.8%	15.2%	6.9m	3.8m	1.1m
	(14.0–15.8)	(14.4–16.1)	(6.0–7.9)	(3.4–4.3)	(1.0–1.3)
2036 introduction	28.8%	26.3%	7.5m	3.7m	1.1m
	(27.0–31.3)	(24.6–28.7)	(6.5–8.7)	(3.2–4.3)	(0.9–1.3)
Lower coverage	25.3%	24.8%	10.2m	5.5m	1.6m
	(23.5–27.6)	(23.1–27.1)	(8.8–11.8)	(4.8–6.3)	(1.4–1.9)
Higher coverage	36.0%	35.7%	15.1m	8.2m	2.4m
	(33.9–39.0)	(33.6–38.5)	(13.1–17.3)	(7.3–9.4)	(2.2–2.8)
Older ages (campaign for ages 18-55)	27.1%	28.9%	13.8m	7.6m	2.3m
	(25.7–29.0)	(27.6–30.7)	(12.2–15.5)	(7.0–8.5)	(2.1–2.6)
Elderly ages (campaign for ages 61+, routine age 60)	6.2%	6.1%	3.1m	1.6m	0.5m
	(5.6–7.0)	(5.4–6.9)	(2.6–3.6)	(1.5–1.8)	(0.4–0.5)

Table S8.1Health impact results for the M72/AS01E scenarios

*Abbreviations: IRR = incidence rate reduction, MRR = mortality rate reduction.* 



Figure S8.3 Incidence and mortality rate reductions in 2050 for the BCG-revaccination scenarios



Figure S8.4 Cumulative tuberculosis cases, treatments, and deaths averted between 2025 and 2050 for the BCG-revaccination scenarios

The horizontal line is the median value of the Basecase for each vaccine, and the vertical line separates vaccine profile and delivery scenarios.

Scenario	IRR in 2050 (%)	MRR in 2050 (%)	Cumulative cases averted 2025–2050	Cumulative treatments averted 2025–2050	Cumulative deaths averted 2025–2050
Basecase	20.7%	20.0%	9.0m	4.8m	1.5m
	(19.0–23.4)	(18.4–22.6)	(7.8–10.4)	(4.2–5.7)	(1.3–1.8)
70% Efficacy	30.0%	29.0%	13.2m	7.0m	2.2m
	(27.6–33.6)	(26.7–32.5)	(11.4–15.2)	(6.1–8.3)	(1.9–2.6)
5 years duration of protection	14.6%	14.4%	6.6m	3.5m	1.1m
	(13.3–16.6)	(13.1–16.4)	(5.8–7.6)	(3.1–4.2)	(1.0–1.3)
15 years duration of protection	24.0%	23.0%	10.1m	5.3m	1.7m
	(22.1–27.0)	(21.1–25.9)	(8.8–11.6)	(4.7–6.4)	(1.5–2.0)
20 years duration of protection	26.1%	24.9%	10.8m	5.7m	1.8m
	(24.1–29.4)	(22.9–27.9)	(9.4–12.4)	(5.0–6.8)	(1.6–2.1)
Prevention of infection and disease	28.4%	27.5%	12.4m	6.6m	2.1m
	(26.2–31.9)	(25.3–30.8)	(10.8–14.4)	(5.8–7.9)	(1.8–2.5)
Efficacious with any infection status at vaccination	21.6%	20.9%	9.4m	5.0m	1.6m
	(19.9–24.3)	(19.2–23.5)	(8.2–10.8)	(4.4–5.9)	(1.4–1.9)
2031 introduction	17.0%	16.3%	5.6m	2.8m	0.9m
	(15.4–19.3)	(14.8–18.6)	(4.9–6.5)	(2.4–3.4)	(0.8–1.1)
Lower coverage	19.0%	18.3%	8.1m	4.3m	1.4m
	(17.4–21.4)	(16.8–20.7)	(7.1–9.4)	(3.8–5.2)	(1.2–1.6)
Higher coverage	22.3%	21.6%	9.7m	5.2m	1.6m
	(20.5–25.1)	(19.8–24.4)	(8.5–11.2)	(4.5–6.2)	(1.4–1.9)
Older ages (campaign for ages 16-34, routine age 15)	21.6%	20.7%	9.7m	5.3m	1.6m
	(19.7–24.4)	(18.8–23.4)	(8.3–11.4)	(4.7–6.2)	(1.4–1.9)
Elderly ages (campaign for ages 61+, routine age 60)	0.8%	0.7%	0.3m	0.1m	0.04m
	(0.7–0.9)	(0.6–0.8)	(0.2–0.3)	(0.1–0.2)	(0.03–0.05)

 Table S8.2
 Health impact results for the BCG-revaccination scenarios

*Abbreviations: IRR = incidence rate reduction, MRR = mortality rate reduction.* 

#### 8.3 India NTEP scenario

Considering the current NTEP tuberculosis targets, we evaluated an additional scenario. This scenario assumed a vaccine with 40% efficacy to prevent infection with 10-years protection and efficacious with no current infection at vaccination. This vaccine was introduced at the start of 2023 routinely to age 18 and as a campaign for ages 19 and above, with scale up to 80% vaccine coverage over two years. We found that a vaccine aligning with those characteristics could reduce incidence and mortality rates by 8–10% in 2030 and prevent 1.4 million cases and 160 thousand deaths by 2030 compared to no-new-vaccine (Table S8.3).

#### Table S8.3Health impact results from the India NTEP scenario

	Incidence ra (%	nte reduction ⁄₀)	Mortality ra (%	Mortality rate reduction (%)		Cumulative cases averted Cumulative (1000s) (10		eaths averted D0s)
	2025	2030	2025	2030	2023–2025	2023–2030	2023–2025	2023-2030
India NTEP scenario	5.7% (5.3–6.4)	9.9% (9.0–11.2)	1.6% (1.4–2.0)	8.0% (7.3–9.2)	268.5 (235.3–310.7)	1,427.8 (1,246.4–1,656.9)	10.7 (9.1–13.8)	159.9 (139.7–191.9)

#### 9. Economic results

#### 9.1 M72/AS01<sub>E</sub> scenarios





Figure S9.1 Cost-effectiveness plane for M72/AS01<sub>E</sub> scenarios

*Abbreviations:* DALYs = disability-adjusted life years, USD\$ = United States Dollars.

Points are the mean incremental costs and mean incremental DALYs averted for each scenario compared to the costs and DALYs from the no-new-vaccine baseline. The solid line represents 1x GDP, the dashed line represents the Ochalek upper bound, and the dotted line represents the Ochalek lower bound. The 20 years protection and 60% efficacy scenarios for the M72/AS01<sub>E</sub> vaccine overlap and appear as one single point on the figure.

# Table S9.1Incremental DALYs averted, incremental costs averted, and ICERs from the health-system<br/>and societal perspectives for the M72/AS01<sub>E</sub> scenarios (mean, 95% uncertainty range)

	Incremental	Health-syste	m perspective	Societal perspective		
Scenario	DALYs averted between 2025–2050 (millions)	Incremental costs between 2025–2050 (\$, millions)	ICERs (\$/DALY averted)	Incremental costs between 2025–2050 (\$, millions)	ICERs (\$/DALY averted)	
Basecase	36.9	5,330	145	5,121	139	
	(32.5–42.9)	(3,083–8,574)	(82–237)	(2,860–8,375)	(77–229)	
60% efficacy	43.1	5,047	117	4,803	111	
	(38.0–50.1)	(2,807–8,298)	(64–196)	(2,543–8,063)	(59–188)	
70% efficacy	49.0	4,780	98	4,502	92	
	(43.2–56.9)	(2,516–8,063)	(50–167)	(2,235–7,783)	(45–160)	
5 years protection	28.0	5,739	205	5,581	199	
	(24.6–32.7)	(3,507–9,000)	(123–326)	(3,337–8,826)	(118–317)	
15 years protection	40.8	5,148	126	4,916	120	
	(36.0–47.4)	(2,904–8,386)	(70–210)	(2,652–8,174)	(65–202)	
20 years protection	43.1	5,042	117	4,797	111	
	(38.0–50.0)	(2,802–8,293)	(64–196)	(2,536–8,058)	(58–188)	
Prevention of infection and disease	46.9	4,875	104	4,609	98	
	(41.3–54.5)	(2,630–8,145)	(55–176)	(2,343–7,877)	(50–170)	
Efficacy with current infection at vaccination	20.5	6,077	296	5,961	290	
	(18.2–23.5)	(3,856–9,353)	(186–456)	(3,727–9,213)	(182–447)	
2036 introduction	18.5	4,437	240	4,332	234	
	(16.2–21.6)	(2,762–6,877)	(145–377)	(2,656–6,774)	(141–368)	
Lower coverage	29.3	4,068	139	3,902	133	
	(25.8–34.2)	(2,337–6,553)	(78–228)	(2,166–6,398)	(74–220)	
Higher coverage	43.9	6,616	151	6,366	145	
	(38.8–51.0)	(3,852–10,621)	(86–245)	(3,572–10,381)	(81–237)	
Older ages (campaign for ages 18–55)	38.5	7,114	185	6,879	179	
	(34.8–43.2)	(4,177–11,349)	(108–294)	(3,940–11,048)	(102–287)	
Elderly ages (campaign for ages 61+, routine age 60)	5.3	3,233	615	3,183	606	
	(4.7–5.9)	(2,074–4,967)	(397–933)	(2,028–4,889)	(387–922)	

*Abbreviations:* DALYs = disability-adjusted life years, ICERs = incremental cost-effectiveness ratio, US\$ = United States Dollar. Values in cells are the mean and 95% uncertainty ranges.

#### Budget impact analysis





Figure S9.3 Basecase M72/AS01<sub>E</sub> scenario incremental discounted costs (USD\$, millions) by year

Abbreviations: DS-TB = drug-susceptible tuberculosis, RR-TB = rifampicin-resistant tuberculosis, USD = United States dollars.

Table S9.2Total vaccination costs, and incremental diagnostic, treatment, and net costs between 2025–<br/>2050 for the M72/AS01E scenarios

Scenario	Vaccination costs (US\$, millions)	DS-TB diagnostic costs (US\$, millions)	RR-TB diagnostic costs (US\$, millions)	DS-TB treatment costs (US\$, millions)	RR-TB treatment costs (US\$, millions)	Incremental cost (US\$, millions)
Basecase	7,018	-84	-3	-1,183	-418	5,331
	(4,769–10,349)	(-103– -67)	(-100.01)	(-1,467– -941)	(-501– -352)	(3,083–8,574)
60% efficacy	7,019	-98	-3	-1,383	-488	5,047
	(4,770–10,351)	(-121– -79)	(-120.02)	(-1,715– -1,099)	(-584– -411)	(2,807–8,298)
70% efficacy	7,020	-111	-3	-1,571	-555	4,780
	(4,771–10,352)	(-137– -89)	(-140.02)	(-1,945– -1,249)	(-664– -467)	(2,516–8,063)
5 years protection	7,017	-64	-2	-896	-316	5,739
	(4,769–10,348)	(-79– -51)	(-80.01)	(-1,115– -712)	(-379– -266)	(3,507–9000)
15 years protection	7,018	-93	-3	-1,312	-463	5,148
	(4,770–10,350)	(-115– -75)	(-120.02)	(-1,625– -1,043)	(-554– -390)	(2,904–8,386)
20 years protection	7,019	-98	-3	-1,386	-490	5,042
	(4,770–10,350)	(-121– -79)	(-120.02)	(-1,7171,102)	(-585– -413)	(2,802–8,293)
Prevention of infection and disease	7,019	-107	-3	-1,504	-531	4,875
	(4,770–10,351)	(-131– -85)	(-130.02)	(-1,867– -1,196)	(-635– -448)	(2,630–8,145)
Efficacy with current infection at vaccination	7,016	-47	-1	-658	-233	6,077
	(4,768–10,346)	(-57–-38)	(-6– -0.007)	(-806– -528)	(-276– -195)	(3,856–9,353)
2036 introduction	5,282	-42	-1	-593	-209	4,437
	(3,592–7,787)	(-5234)	(-50.007)	(-739– -470)	(-253– -174)	(2,762–6,877)
Lower coverage	5,410	-67	-2	-941	-332	4,068
	(3,682–7,970)	(-83– -53)	(-80.01)	(-1,171– -748)	(-399– -279)	(2,338–6,553)
Higher coverage	8,629	-100	-3	-1,412	-499	6,616
	(5,859–12,734)	(-123– -80)	(-120.02)	(-1,747–-1,123)	(-596– -420)	(3,852–10,621)
Older ages (campaign for ages 18–55)	9,017	-95	-3	-1,334	-471	7,115
	(6,097–13,346)	(-11477)	(-120.01)	(-1,6101,072)	(-551– -402)	(4,177–11,349)
Elderly ages (campaign for ages 61+, routine age 60)	3,634	-20	-1	-282	-99	3,233
	(2,474–5,356)	(-25– -16)	(-3– -0.003)	(-348– -227)	(-119– -84)	(2,074–4,967)

Abbreviations: DS-TB = drug-susceptible tuberculosis, RR-TB = rifampicin resistant tuberculosis, US\$ = United States Dollars. Values in cells are the mean and 95% uncertainty ranges.

#### 9.2 BCG-revaccination scenarios

#### Cost-effectiveness analysis



Figure S9.4 Cost-effectiveness plane for BCG-revaccination scenarios

*Abbreviations:* DALYs = disability-adjusted life years, USD\$ = United States Dollars.

Points are the mean incremental costs and mean incremental DALYs averted for each scenario compared to the costs and DALYs from the no-new-vaccine baseline. The solid line represents 1x GDP, the dashed line represents the Ochalek upper bound, and the dotted line represents the Ochalek lower bound. The 20 years protection and 60% efficacy scenarios for the  $M72/AS01_E$  vaccine overlap and appear as one single point on the figure.

# Table S9.3Incremental DALYs averted, incremental costs averted, and ICERs from the health system<br/>and societal perspectives for BCG-revaccination scenarios

	Incremental	Health-system	m perspective	Societal perspective		
Scenario	DALYs averted between 2025– 2050 (millions)	Incremental costs between 2025–2050 (\$, millions)	ICERs (\$/DALY averted)	Incremental costs between 2025–2050 (\$, millions)	ICERs (\$/DALY averted)	
Basecase	29.1	653	22	502	17	
	(25.1–34.6)	(-419–2,179)	(cost-saving-79)	(-563–2,030)	(cost-saving–71)	
70% Efficacy	42.8	82	2	-140	cost-saving	
	(37.0–51.0)	(-1058–1,684)	(cost-saving-40)	(-1,257–1,425)	(cost-saving-33)	
5 years protection	22.1	964	44	851	39	
	(19.0–26.3)	(-78–2,456)	(cost-saving-116)	(-195–2,343)	(cost-saving-111)	
15 years protection	32.4	505	16	336	10	
	(27.9–38.6)	(-576–2,049)	(cost-saving–67)	(-736–1,880)	(cost-saving–59)	
20 years protection	34.4	417	12	237	7	
	(29.7–40.9)	(-678–1,970)	(cost-saving–60)	(-836–1,792)	(cost-saving–53)	
Prevention of infection and disease	40.6	175	4	-35	cost-saving	
	(35.0–48.4)	(-953–1,763)	(cost-saving-44)	(-1133–1,526)	(cost-saving-38)	
Efficacy with any infection status at vaccination	30.4	604	20	446	15	
	(26.4–36.1)	(-466–2,145)	(cost-saving-74)	(-628–1,984)	(cost-saving–67)	
2031 introduction	16.2	539	33	456	28	
	(13.9–19.3)	(-145–1,522)	(cost-saving–97)	(-227–1,438)	(cost-saving–92)	
Lower coverage	26.3	555	21	418	16	
	(22.6–31.3)	(-390–1,900)	(cost-saving-76)	(-515–1,764)	(cost-saving–69)	
Higher coverage	31.7	758	24	594	19	
	(27.3–37.7)	(-437–2,465)	(cost-saving-82)	(-591–2,301)	(cost-saving–74)	
Older ages (campaign for ages 16–34, routine age 15)	30.0	1,554	52	1,384	46	
	(26.1–35.6)	(-111–3,953)	(cost-saving–135)	(-301–3,773)	(cost-saving-131)	
Elderly ages (campaign for ages 61+,	0.4	1,617	3,594	1,612	3,585	
routine age 60)	(0.4–0.6)	(686–2,997)	(1,485–6,734)	(681–2,989)	(1,478–6,725)	

Abbreviations: DALYs = disability-adjusted life years, ICERs = incremental cost-effectiveness ratio, US\$ = United States Dollar. Values in cells are the mean and 95% uncertainty ranges.

#### Budget impact analysis



Figure S9.6 Basecase BCG-revaccination scenario incremental discounted costs (US\$, millions) by year

Abbreviations: DS-TB = drug-susceptible tuberculosis, RR-TB = rifampicin-resistant tuberculosis, USD = United States dollars.

## Table S9.4Total vaccination costs, and incremental diagnostic, treatment, and net costs between<br/>2025–2050 for the BCG-revaccination scenarios

Scenario	Vaccination costs (US\$, millions)	DS-TB diagnostic costs (US\$, millions)	RR-TB diagnostic costs (US\$, millions)	DS-TB treatment costs (US\$, millions)	RR-TB treatment costs (US\$, millions)	Incremental cost (US\$, millions)
Basecase	1,870	-61	-2	-854	-301	653
	(831–3,408)	(-77– -48)	(-80.01)	(-1,088– -674)	(-368– -251)	(-419–2,179)
70% efficacy	1,875	-89	-3	-1,257	-444	85
	(833–3,417)	(-113– -71)	(-110.02)	(-1,600– -994)	(-540– -368)	(-1058–1,684)
5 years protection	1,873	-45	-1	-638	-225	964
	(833–3,413)	(-57– -36)	(-6– -0.008)	(-811– -505)	(-276– -187)	(-78–2,456)
15 years protection	1,869	-68	-2	-956	-338	506
	(831–3,405)	(-86– -54)	(-80.01)	(-1,220– -754)	(-411– -280)	(-576–2,049)
20 years protection	1,868	-72	-2	-1,018	-359	417
	(831–3,403)	(-91– -57)	(-9– -0.01)	(-1,296– -802)	(-438– -298)	(-678–1,970)
Prevention of infection and disease	1,871	-84	-3	-1,189	-420	175
	(832–3,409)	(-107– -67)	(-10– -0.01)	(-1,517– -938)	(-512348)	(-953–1,763)
Efficacy with any infection at vaccination	1,878	-63	-2	-893	-316	604
	(835–3,424)	(-80– -50)	(-80.01)	(-1,142– -705)	(-384262)	(-466–2,145)
2031 introduction	1,211	-33	-1	-471	-166	539
	(537–2,208)	(-4326)	(-4– -0.006)	(-605– -368)	(-205– -137)	(-145–1,522)
Lower coverage	1,655	-55	-2	-772	-272	555
	(743–3,003)	(-69– -43)	(-7– -0.009)	(-984– -609)	(-333– -226)	(-390–1,900)
Higher coverage	2,083	-66	-2	-929	-328	758
	(918–3,807)	(-83– -52)	(-80.01)	(-1,184– -735)	(-400– -273)	(-437–2,465)
Older ages (campaign for ages 16-	2,926	-68	-2	-963	-340	1,554
34, routine age 15)	(1,264–5,390)	(-86– -54)	(-80.01)	(-1,219– -756)	(-414282)	(-111–3,953)
Elderly ages (campaign for ages 61+, routine age 60)	1,652	-2	-0.1	-24	-9	1,617
	(718–3,036)	(-21)	(-0.2–0)	(-3119)	(-117)	(686–2,997)

Abbreviations: DS-TB = drug-susceptible tuberculosis, RR-TB = rifampicin resistant tuberculosis, US = United States Dollars. Values in cells are the mean and 95% uncertainty ranges.

#### References

- 1. Clark RA, Mukandavire C, Portnoy A, et al. The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study. *The Lancet Global Health* (in press).
- 2. United Nations, Department of Economic and Social Affairs, Population Division. World Population Projections [2019 Revision]. 2019. https://population.un.org/wpp/Download/Standard/Population/ (accessed Nov 2, 2022).
- Tiemersma EW, Werf MJ van der, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review. *PLOS One*. 2011;6(4):e17601. doi:10.1371/journal.pone.0017601
- 4. Quaife M, Houben RMGJ, Allwood B, et al. Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. *Lancet Respir Med*. 2020;8(4):332-333. doi:10.1016/S2213-2600(20)30039-4
- 5. Prem K, Zandvoort K van, Klepac P, et al. Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. *PLOS Comput Biol.* 2021;17(7):e1009098. doi:10.1371/journal.pcbi.1009098
- 6. World Health Organization. WHO TB burden estimates. CSV files to download. 2022. https://www.who.int/tb/country/data/download/en/ (accessed Nov 2, 2022).
- 7. World Health Organization. Case Notifications. CSV files to download. 2022. https://www.who.int/tb/country/data/download/en/ (accessed Nov 2, 2022).
- Emery JC, Dodd PJ, Banu S, et al. Estimating the contribution of subclinical tuberculosis disease to transmission—an individual patient data analysis from prevalence surveys. *medRxiv* 2022; published online June 14. https://doi.org/10.1101/2022.06.09.22276188 (preprint).
- Emery JC, Richards AS, Dale KD, et al. Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. *Proc Biol Sci.* 2021;288(1943):20201635. doi: 10.1098/rspb.2020.1635.
- 10. Abu-Raddad L, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. *Proc Natl Acad Sci U S A*. 2009;**106(33)**:13980-13985.
- 11. Dye C, Williams BG. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface. 2008;5(23):653-662. doi:10.1098/rsif.2007.1138
- Marx FM, Dunbar R, Enarson DA, et al. The Temporal Dynamics of Relapse and Reinfection Tuberculosis After Successful Treatment: A Retrospective Cohort Study. *Clin Infect Dis.* 2014;58(12):1676-1683. doi:10.1093/cid/ciu186
- 13. Gomes MGM, Franco AO, Gomes MC, Medley GF. The reinfection threshold promotes variability in tuberculosis epidemiology and vaccine efficacy. *Proc R Soc B Biol Sci.* 2004;**271(1539)**:617-623.
- 14. Dangisso MH, Woldesemayat EM, Datiko DG, Lindtjørn B. Long-term outcome of smear-positive tuberculosis patients after initiation and completion of treatment: A ten-year retrospective cohort study. *PLOS One*. 2018;**13(3)**:e0193396. doi:10.1371/journal.pone.0193396
- 15. Sutherland I, Svandová E, Radhakrishna S. The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. *Tubercle*. 1982;**63(4)**:255-268. doi:10.1016/s0041-3879(82)80013-5
- 16. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. *Epidemiol Infect*. 1997;**119(2)**:183-201.

- Gabriela M. Gomes M, Rodrigues P, Hilker FM, et al. Implications of partial immunity on the prospects for tuberculosis control by post-exposure interventions. J Theor Biol. 2007;248(4):608-617. doi:10.1016/j.jtbi.2007.06.005
- 18. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33(7):1034-1039. doi:10.1086/322671
- 19. World Health Organization. Global Tuberculosis Report 2020.; 2020.
- Andrianakis I, Vernon I, McCreesh N, et al. History matching of a complex epidemiological model of human immunodeficiency virus transmission by using variance emulation. *J R Stat Soc Ser C Appl Stat.* 2017;66(4):717-740. doi:10.1111/rssc.12198
- Andrianakis I, Vernon IR, McCreesh N, et al. Bayesian History Matching of Complex Infectious Disease Models Using Emulation: A Tutorial and a Case Study on HIV in Uganda. *PLOS Comput Biol.* 2015;11(1):e1003968. doi:10.1371/journal.pcbi.1003968
- Goldstein M. Bayes Linear Analysis for Complex Physical Systems Modeled by Computer Simulators. In: Dienstfrey AM, Boisvert RF, eds. Uncertainty Quantification in Scientific Computing. Vol 377. *IFIP Advances in Information and Communication Technology*. Springer Berlin Heidelberg; 2012:78-94. doi:10.1007/978-3-642-32677-6 6
- 23. Williamson D, Goldstein M, Allison L, et al. History matching for exploring and reducing climate model parameter space using observations and a large perturbed physics ensemble. *Clim Dyn.* 2013;**41**:1703-1729. doi:10.1007/s00382-013-1896-4
- 24. Iskauskas A. hmer: History Matching and Emulation Package. Published online 2022. https://CRAN.R-project.org/package=hmer (accessed Nov 2, 2022)
- 25. Iskauskas A, Vernon I, Goldstein M, et al. Emulation and History Matching using the hmer Package. Published online September 12, 2022. http://arxiv.org/abs/2209.05265 (accessed Dec 2, 2022)
- 26. Jabot F, Faure T, Dumoulin N. EasyABC: performing efficient approximate Bayesian computation sampling schemes using R. O'Hara RB, ed. Methods Ecol Evol. 2013;4(7):684-687. doi:10.1111/2041-210X.12050
- 27. Roberts GO, Rosenthal JS. Examples of Adaptive MCMC. *J Comput Graph Stat.* 2009;**18(2)**:349-367. doi:10.1198/jcgs.2009.06134
- 28. World Health Organization. WHO TB incidence estimates disaggregated by age group, sex and risk factor. CSV files to download. Published 2022. https://www.who.int/tb/country/data/download/en/ (accessed Nov 2, 2022).
- 29. WHO. Global tuberculosis report. 2021. https://apps.who.int/iris/ handle/10665/346387 (accessed Nov 2, 2022).
- 30. Pandey S, Chadha VK, Laxminarayan R, Arinaminpathy N. Estimating tuberculosis incidence from primary survey data: a mathematical modeling approach. *Int J Tuberc Lung Dis.* 2017;**21(4)**:366-374. doi:10.5588/ijtld.16.0182
- Mandal S, Chadha VK, Laxminarayan R, Arinaminpathy N. Counting the lives saved by DOTS in India: a modelbased approach. *BMC Med*. 2017;15(1):47. doi:10.1186/s12916-017-0809-5
- 32. Indian Council of Medical Research (ICMR). National TB Prevalence Survey India 2019-2021.; 2022:1-212.
- Singh SK, Kashyap GC, Puri P. Potential effect of household environment on prevalence of tuberculosis in India: evidence from the recent round of a cross-sectional survey. *BMC Pulm Med.* 2018;18(1):66. doi:10.1186/s12890-018-0627-3
- Frascella B, Richards AS, Sossen B, et al. Subclinical tuberculosis disease a review and analysis of prevalence surveys to inform definitions, burden, associations and screening methodology. *Clin Infect Dis.* 2021;73(3):e830e841. doi:10.1093/cid/ciaa1402

- 35. Shewade HD, Gupta V, Satyanarayana S, et al. Are we missing 'previously treated' smear-positive pulmonary tuberculosis under programme settings in India? A cross-sectional study. *F1000Res.* 2019;**8**:338. doi: 10.12688/f1000research.18353.2.
- 36. Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. *N Engl J Med.* 2019;**381(25):**2429-2439. doi:10.1056/NEJMoa1909953
- Nemes E, Geldenhuys H, Rozot V, al E. Prevention of M. tuberculosis Infection with H4:1C31 Vaccine or BCG Revaccination. N Engl J Med. 2018;379:138-149.
- 38. Pelzer PT, Seeley J, Sun FY, et al. Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines. *PLOS Global Public Health* 2022; **2(5)**: e0000076.
- Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;**396(10258)**:1204-1222. doi:10.1016/S0140-6736(20)30925-9
- 40. United Nations Development Programme. Human Development Report: Life Expectancy by Country. United Nations; 2020. https://hdr.undp.org/data-center (accessed June 13, 2022)
- 41. Harris RC, Quaife M, Weerasuriya C, et al. Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India. *Nat Commun.* 2022;**13(1)**:602. doi:10.1038/s41467-022-28234-7
- 42. Weerasuriya CK, Harris RC, Quaife M, McQuaid CF, White RG, Gomez GB. Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis. *Vaccines*. 2021;9(3):245. doi:10.3390/vaccines9030245
- UNICEF. Bacillus Calmette–Guérin (BCG) vaccine price data. Published 2021. https://www.unicef.org/supply/documents/bacillus-calmettegu%C3%A9rin-bcg-vaccine-price-data (accessed Dec 13, 2022).
- 44. Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. *Value Health*. 2016;**19(8)**:921-928. doi:10.1016/j.jval.2016.04.015
- 45. WHO. The End TB Strategy. Aug 16, 2015. https://www.who.int/ publications/i/item/WHO-HTM-TB-2015.19 (accessed Nov 2, 2022).
- 46. Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. *Trans R Soc Trop Med Hyg.* 2016;**110(3)**:148-150. doi:10.1093/trstmh/trv108
- 47. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. *BMJ Glob Health*. 2018;**3(6)**:e000964. doi:10.1136/bmjgh-2018-000964
- 48. Vassall A, Kampen S van, Sohn H, Michael JS, John KR, Boon S den, et al. Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis. *PLOS Medicine*. 2011;8(11):e1001120.
- 49. Muniyandi M, Lavanya J, Karikalan N, Saravanan B, Senthil S, Selvaraju S, et al. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India. *International Health*. 2021;**13(6)**:536–44.
- 50. Chatterjee S, Toshniwal MN, Bhide P, Sachdeva KS, Rao R, Laurence YV, et al. Costs of TB services in India. *Int J Tuberc Lung Dis.* 2021;**25(12)**:1013–8.
- 51. Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE, et al. Estimated generic prices for novel treatments for drug-resistant tuberculosis. *J Antimicrob Chemother*. 2017;**72(4)**:1243–52.

- 52. Sinha P, Carwile M, Bhargava A, Cintron C, Acuna-Villaorduna C, Lakshminarayan S, et al. How much do Indians pay for tuberculosis treatment? A cost analysis. Public Health Action. 2020;**10(3)**:110–7.
- 53. Sarin R, Vohra V, Singla N, Thomas B, Krishnan R, Muniyandi M. Identifying costs contributing to catastrophic expenditure among TB patients registered under RNTCP in Delhi metro city in India. *Indian J Tuberc*. 2019;66(1):150–7.
- 54. Chandra A, Kumar R, Kant S, Parthasarathy R, Krishnan A. Direct and indirect patient costs of tuberculosis care in India. *Trop Med Int Health*. 2020;**25(7)**:803–12.
- Gavi The Vaccine Alliance. GAVI Alliance Vaccine Introduction Grant and Operational Support for Campaigns Policy. Version No. 1.0. Geneva: Gavi, The Vaccine Alliance. 2 April 2013. www.gavi.org (accessed July 12, 2018).
- 56. Arinaminpathy N, Nandi A, Vijayan S, Jha N, Nair SA, Kumta S, et al. Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness. *BMJ Glob Health*. 2021;6(10):e006114.
- 57. National Tuberculosis Elimination Programme. National Strategic Plan to End Tuberculosis in India 2017–2025. New Delhi: Ministry of Health with Family Welfare, 2017.
- 58. UNICEF. Costs of Vaccinating a Child. Published 2020. https://immunizationeconomics.org/recent-activity/2021/6/15/standard-costs-of-vaccinating-a-child (accessed Jan 20, 2021).